Diuretics

ApprovedSmall molecule

Boehringer Ingelheim

Diuretics is one of 221 small molecule programs targeting Ascites. It is currently in Approved.

Indications

Total Trials

Active Trials

220

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesActive, not recruiting

AL AmyloidosisActive, not recruiting

HypertensionActive, not recruiting

Heart FailureActive, not recruiting

CirrhosisActive, not recruiting

Heart DiseaseActive, not recruiting

Sleep ApneaActive, not recruiting

AscitesPhase 2/Phase 3

Active, not recruiting

AL AmyloidosisPhase 2

Active, not recruiting

HypertensionPhase 3

Active, not recruiting

Heart FailurePhase 3

Active, not recruiting

CirrhosisApproved

Active, not recruiting

Heart DiseasePhase 3

Active, not recruiting

Sleep ApneaPhase 3

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Diuretics

Boehringer Ingelheim

Approved

3 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Amidate

Pfizer

Preclinical

1 6

LCZ696

Novartis

Preclinical

15 7

Zemplar

Savaysa

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 10

Xifaxan

SSalix

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Failure3 trials

ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE

Terminated·NNiguarda Hospital·Phase 3·NCT01290146·13 enrolled

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00391846·252 enrolled

Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration

Completed·UUniversity Hospital, Ghent·Phase 3·NCT01138683·1 enrolled

Hypertension2 trials

Effect of Caldine® on Renal Function in Balanced Hypertension

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02240641·5,417 enrolled

Hypertension Detection and Follow-up Program (HDFP)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000485

Angiotensin Receptor Blockers1 trial

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02215733·1,165,781 enrolled

Critically Ill Patients1 trial

Effects of Fluid Balance Control in Critically Ill Patients

Completed·—·N/A·NCT02765009·1,411 enrolled

Heart Disease1 trial

Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)

Completed·UUniversity of Minnesota·Phase 3·NCT00000487

7 more indications

Sleep Apnea1 trial

Effect of Antihypertensive Agents Over Sleep Apnea

Completed·HHospital de Clinicas de Porto Alegre·Phase 3·NCT01896661·53 enrolled

Cirrhosis1 trial

Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis

Completed·UUniversity of Bologna·Phase 4·NCT01288794·431 enrolled

AL amyloidosis1 trial

Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis

Terminated·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT01511263·86 enrolled

CAR1 trial

Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures

Completed·MMedtronic Cardiac Rhythm and Heart Failure·Phase 2·NCT01370564·21 enrolled

Safety and Efficacy1 trial

To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03645642·8 enrolled

Critical Care1 trial

Mean Systemic Filling Pressure Continuous Diuretics Critical Care Patients

Completed·CCatharina Ziekenhuis Eindhoven··NCT03395951·18 enrolled

Ascites1 trial

Empagliflozin as a Novel Therapy in Refractory Ascites

Completed·—·Phase 2/3·NCT05430243·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Diuretics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diuretics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diuretics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

Diuretics

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Failure3 trials

Hypertension2 trials

Angiotensin Receptor Blockers1 trial

Critically Ill Patients1 trial

Heart Disease1 trial

Sleep Apnea1 trial

Cirrhosis1 trial

AL amyloidosis1 trial

CAR1 trial

Safety and Efficacy1 trial

Critical Care1 trial

Ascites1 trial

References

Drug Info

Quick Facts

Related News